TAKEDA-SPONSORED
Psych Congress Poster Details
Available for Review at the 2026 Psych Congress
September 15 – 19, 2026 | New Orleans, LA
Neuroscience/ Narcolepsy
#158
Effect of the oral orexin receptor 2 agonist oveporexton (TAK-861) on functional impacts of narcolepsy type 1: Results from two phase 3 studies
G Plazzi, Y Dauvilliers, F Pizza, S Crawford, T Olsson, Y Pyatkevich, H Romero, Y Savva, B Yao, M Etherton
#159
Oveporexton (TAK-861) improves cognitive symptoms in patients with narcolepsy type 1: Results from two randomized, placebo-controlled phase 3 trials
F Pizza, Y Dauvilliers, R del Rio Villegas, E Mignot, T E. Scammell, T Banerjee, A Cai, M Etherton, E Stukalin, V Khachadourian, P Maruff, T Olsson, R H. Pietrzak, D Volfson, B Harel
#160
A Network Meta-Analysis Comparing the Efficacy of Oveporexton With Current Treatments in Narcolepsy Type 1
ML Zichlin, Rolf Fronczek, SL Bermingham, S Crawford, M Dalal, K Fahrbach, M Akin-Fajiye, S Ronnebaum, M Thorpy
#161
Estimating the Proportion of People with Narcolepsy Type 1 Achieving Normal Epworth Sleepiness Scale Scores and Reduction in Cataplexy Frequency with Pitolisant, Sodium Oxybate, and Oveporexton
SL Bermingham, T Matos, K Campbell, M Zichlin, S Wolowacz
#163
Effects of Treatment with Oveporexton, an Orexin Receptor 2 Agonist, on Sleep in People with Narcolepsy Type 1: Phase 3 Results
L Barateau, Y Gong, Y Dauvilliers, T E. Scammell, E Mignot, B Yao, Y Du, T Banerjee, A Cai, A Ganguly, T Olsson, Y Pyatkevich, P Tierney, B Tracey, D Volfson
#167
Understanding patient and provider perspectives of narcolepsy type 1 symptoms and treatments in the US: Results from real-world clinical practices
Christine Ulbricht, Sarah Cotton, Lucy Hargreaves, Becky Storm, Betty Lorenz, Amy Duhig
#168
Functional and Psychosocial Burden of Narcolepsy Type 1: Concordance Between Patient and Physician Reports
Christine Ulbricht, Sarah Cotton, Lucy Hargreaves, Becky Storm, Betty Lorenz, Amy Duhig